| 肝细胞癌的分子靶向治疗 |
| |
| 引用本文： | 罗荣城,李爱民.肝细胞癌的分子靶向治疗[J].传染病信息,2009,22(2):118-122. |
| |
| 作者姓名： | 罗荣城 李爱民 |
| |
| 作者单位： | 南方医科大学南方医院肿瘤中心,广州,510515 |
| |
| 摘 要： | 分子靶向治疗是近10年来肿瘤治疗领域的重大突破，在肺癌、恶性胃肠间质细胞瘤、恶性淋巴瘤、肠癌、乳腺癌等肿瘤的治疗中已获得很大的成功，尤其HCC的分子靶向治疗在小分子靶向治疗上取得了令人瞩目的新进展，特别是多靶点药物索拉非尼在HCC的靶向治疗中取得的成功，使HCC分子靶向全身治疗有了新的标准。
|
| 关 键 词： | 肝细胞癌 分子靶向治疗 索拉非尼 |
Molecular targeted therapy for hepatocellular carcinoma |
| |
| Luo Rongcheng,Li Aimin.Molecular targeted therapy for hepatocellular carcinoma[J].Infectious Disease Information,2009,22(2):118-122. |
| |
| Authors: | Luo Rongcheng Li Aimin |
| |
| Institution: | Luo Rongcheng,Li Aimin South Hospital Affiliated to South Medical University,Guangzhou 510515,China |
| |
| Abstract: | In recent decade,molecular targeted therapy,as an important breakthrough in tumor therapies,has achieved success in the treatment of lung carcinoma,maligant gastrointestinal stromal tumors,maligant lymphadenoma,intestinal neoplasms and breast cancer.Great progress has been made in small molecular targeted therapy for HCC and sorafenib has been approved as a standard agent for molecular targeted therapy for HCC. |
| |
| Keywords: | hepatocellular carcinoma molecular targeted therapy sorafenib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
